Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sivelestat · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Sivelestat | DRUG | - |
Inclusion Criteria * show evidence of acute lung injury * be on mechanical ventilation Exclusion Criteria * have undergone certain organ transplants * have severe underlying medical problems * be unlikely to survive * be pregnant or breast-feeding
Sivelestat is being studied for the treatment of Adult Respiratory Distress Syndrome, also referred to as acute lung injury. It is an investigational small molecule developed by Eli Lilly and Company and has not been approved for commercial use. Clinical evaluation has focused on hospitalized adult patients with this respiratory condition.
Sivelestat targets ELANE, also known as neutrophil elastase, and acts as an inhibitor of this enzyme. By inhibiting ELANE activity, the drug is designed to reduce enzyme-driven tissue damage in the lungs. This mechanism is the basis for its investigation in acute lung injury and Adult Respiratory Distress Syndrome.
Sivelestat is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company is the sponsor of the clinical program evaluating the drug in respiratory distress syndrome and acute lung injury.
Sivelestat is in Phase 1 clinical development for Adult Respiratory Distress Syndrome. It is an investigational small molecule and is not FDA approved. The program has completed one trial to date, and no trials are currently active.
Sivelestat has been evaluated in one completed clinical trial, NCT00036062, titled a Phase II study to determine the efficacy and safety of Sivelestat in subjects with acute lung injury. The randomized, double-blind study enrolled 600 adults across the United States, Australia, Belgium, Canada, New Zealand, and Spain.